UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK

In re:	Chapter 11
PURDUE PHARMA L.P., *et al.*,	Case No. 19-23649 (RDD)
Debtors.[1]	(Jointly Administered)

**MONTHLY FEE STATEMENT OF CORNERSTONE
RESEARCH FOR COMPENSATION FOR SERVICES
RENDERED AS CONSULTANT TO THE DEBTORS FOR
THE PERIOD FROM
OCTOBER 1, 2020 THROUGH OCTOBER 31, 2020**

Name of Applicant	Cornerstone Research
Applicant's Role in Case	Consultant to Purdue Pharma L.P., *et al.*,
Date Order of Employment Signed	June 11, 2020
Period for which compensation and reimbursement is sought	October 1, 2020 through October 31, 2020

Summary of Total Fees and Expenses Requested	
Total compensation requested in this statement	$341,573.60 (80% of $426,967.00)
Total reimbursement requested in this statement	$111.50
Total compensation and reimbursement requested in this statement	$341,685.10

---

[1] The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

This is a(n):   _X_ Monthly Application_____Interim Application_____Final Application

Pursuant to sections 327, 330, and 331 of chapter 11 of title 11 of the United States Code (the "**Bankruptcy Code**"), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the "**Bankruptcy Rules**"), Rule 2016-1 of the Local Bankruptcy Rules for the United States Bankruptcy Court for the Southern District of New York (the "**Local Rules**"), the *Order Authorizing the Retention and Employment of Cornerstone Research as Consultants for the Debtors Nunc Pro Tunc to January 14, 2020* [ECF No. 1255] (the "**Retention Order**"), and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals*, dated November 21, 2019 [Docket No. 529] (the "**Interim Compensation Order**"), Cornerstone Research, consultant for the above-captioned debtors and debtors in possession (collectively, the "**Debtors**"), submits this *Monthly Fee Statement of Cornerstone Research for Services Rendered as Consultant to the Debtor for the Period from October 1, 2020 Through October 31, 2020* (this "**Fee Statement**").[2] By this Fee Statement, Cornerstone Research seeks (i) compensation in the amount of **$341,573.60**, which is equal to 80% of the total amount of reasonable compensation for actual, necessary consulting services that Cornerstone Research incurred in connection with such services during the Fee Period (i.e., **$426,967.00**) and ii) payment of **$111.50** for the actual, necessary expenses that Cornerstone Research incurred in connection with such services during the Fee Period.

---

[2] The period from October 1, 2020 through and including October 31, 2020, is referred to herein as the "**Fee Period**."

Itemization of Services Rendered and Disbursements Incurred

1.   Attached hereto as **Exhibit A** is a chart of the number of hours expended and

fees incurred (on an aggregate basis) by Cornerstone Research consultants and litigation support

staff during the Fee Period with respect to each project category. As reflected in **Exhibit A**,

Cornerstone Research incurred **$426,967.00** in fees during the Fee Period. Pursuant to this Fee

Statement, Cornerstone Research seeks reimbursement for 80% of such fees, totaling

$341,573.60.

2.   Attached hereto as **Exhibit B** is a chart of Cornerstone Research staff,

including the standard hourly rate for each consultant and litigation support staff member who

rendered services to the Debtors in connection with these chapter 11 cases during the Fee Period

and the title, hourly rate, aggregate hours worked and the amount of fees earned by each individual.

The blended hourly billing rate of consultants for all services provided during the Fee Period is

$491.72.[3]

3.   Attached hereto as **Exhibit C** is a chart of expenses that Cornerstone Research

incurred or disbursed in the amount of $111.50 in connection with providing professional services to

the Debtors during the Fee Period.

4.   Attached hereto as **Exhibit D** are the time records of Cornerstone Research for

The Fee Period organized by month and project category with a daily time log describing the time

spent by each consultant and litigation support staff member during Fee Period.

Notice

5.   The Debtors will provide notice of this Fee Statement in accordance with the

Interim Compensation Order. The Debtors submit that no other or further notice be given.

[Remainder of Page Left Blank Intentionally]

---

[3] The blended hourly billing rate of $491.72 for consultants is derived by dividing the total fees for consultants of
$426,967.00 by the total hours of 868.30.

WHEREFORE, Cornerstone Research, in connection with services rendered on behalf of the Debtors, respectfully requests (i) compensation in the amount of **$341,573.60** which is equal to 80% of the total amount of reasonable compensation for actual, necessary consulting services that Cornerstone Research incurred in connection with such services during the Fee Period (i.e., **$426,967.00**) and ii) payment of **$111.50** for the actual, necessary expenses that Cornerstone Research incurred in connection with such services during the Fee Period**.**

Dated: November 30, 2020
          Boston, Massachusetts

CORNERSTONE RESEARCH

By: */s/ Sally Woodhouse*

699 Boylston Street
Boston, Massachusetts 02116
Telephone: (617) 927-3000
Facsimile: (617) 927-3100

Exhibit A

Fees By Project Category

Project Category	Total Hours	Total Fees
Preparation of Fee Statements	15.30	$ 10,613.50
Claims Valuation	853.00	$ 416,353.50
Total	868.30	$ 426,967.00

Exhibit B

Professional and Paraprofessional Fees

Individual	Title	Hourly Rate	Total Hours Billed	Total Compensation
Professional Fees				
Woodhouse, Sally	Senior Vice President	$ 850.00	9.90	$ 8,415.00
Kovacheva, Penka	Principal	$ 720.00	49.60	$ 35,712.00
Haque, Rezwan	Senior Manager	$ 645.00	67.80	$ 43,731.00
Lee, James	Senior Manager	$ 645.00	71.20	$ 45,924.00
Abraham, Sarah M.	Manager	$ 605.00	31.70	$ 19,178.50
Guo, Fang	Manager	$ 605.00	90.50	$ 54,752.50
Yanguas, Maria Lucia	Associate	$ 545.00	101.40	$ 55,263.00
Russell, Nolan P.	Research Associate	$ 450.00	34.40	$ 15,480.00
King, Kyla M.	Research Associate	$ 410.00	92.40	$ 37,884.00
Desmedt, Maaike	Senior Analyst	$ 380.00	8.50	$ 3,230.00
Aristidou, Andreas	Summer Associate	$ 360.00	100.60	$ 36,216.00
Chen, Yixin	Analyst	$ 345.00	52.30	$ 18,043.50
Guo, Ruihan	Analyst	$ 345.00	44.30	$ 15,283.50
Miller, Robert M.	Analyst	$ 345.00	58.80	$ 20,286.00
Bazak, Eric R.	Analyst	$ 320.00	54.90	$ 17,568.00
		Total	**868.30**	**$ 426,967.00**

Exhibit C

Expense Summary

Expense Category	Service Provider (if applicable)	Total Expenses
Document/Data Acquisition	Various Journal Articles	$ 111.50
Total		$ 111.50

Exhibit D

Time Detail by Project Category and Month

Project Category: Preparation of Fee Statements

Timekeeper	Date	Hours	Narrative
Kovacheva, Penka	10/1/2020	1.1	Reviewed and updated time details for monthly fee statement.
Kovacheva, Penka	10/2/2020	0.5	Updated and finalized monthly fee statement.
Kovacheva, Penka	10/5/2020	1.1	Reviewed and updated time details for monthly fee statement.
Lee, James	10/5/2020	0.8	Reviewed time details for monthly fee statement.
Haque, Rezwan	10/6/2020	2.8	Reviewed time details for monthly fee statement.
Lee, James	10/6/2020	0.3	Reviewed time details for monthly fee statement.
Abraham, Sarah M.	10/7/2020	0.5	Reviewed time details for monthly fee statement.
Haque, Rezwan	10/7/2020	0.7	Reviewed and updated time details for monthly fee statement.
Kovacheva, Penka	10/12/2020	1.6	Reviewed and updated time details for monthly fee statement.
Kovacheva, Penka	10/15/2020	0.1	Organized preparation of monthly fee statement.
Kovacheva, Penka	10/25/2020	1.2	Reviewed and updated monthly fee statement.
Kovacheva, Penka	10/27/2020	0.6	Reviewed and updated monthly fee statement.
Kovacheva, Penka	10/28/2020	3.4	Drafted interim fee application.
Kovacheva, Penka	10/29/2020	0.6	Updated and finalized monthly fee statement.

Total   15.3

8

Project Category: Claims Valuation

Timekeeper	Date	Hours	Narrative
Abraham, Sarah M.	10/1/2020	2.4	Updated personal injury claims valuation analyses.
Chen, Yixin	10/1/2020	2.6	Checked sensitivity analysis of personal injury claims data.
Desmedt, Maaike	10/1/2020	4.0	Analyzed personal injury and NAS claims.
Haque, Rezwan	10/1/2020	0.6	Reviewed agenda for call with counsel regarding claims valuation.
Lee, James	10/1/2020	1.8	Reviewed personal injury claims data.
Lee, James	10/1/2020	4.1	Analyzed personal injury claims data.
Russell, Nolan P.	10/1/2020	2.3	Analyzed personal injury claims data.
Yanguas, Maria Lucia	10/1/2020	1.7	Updated personal injury claims valuation sensitivities.
Yanguas, Maria Lucia	10/1/2020	1.8	Updated personal injury claims analyses.
Yanguas, Maria Lucia	10/1/2020	4.2	Reviewed personal injury claims analyses.
Abraham, Sarah M.	10/2/2020	0.5	Discussed claims valuation analyses with team.
Abraham, Sarah M.	10/2/2020	1.1	Call with counsel regarding personal injury claims valuation.
Abraham, Sarah M.	10/2/2020	2.1	Prepared preliminary valuation analyses for personal injury claims.
Chen, Yixin	10/2/2020	3.1	Conducted sensitivity analysis on personal injury claims data.
Desmedt, Maaike	10/2/2020	0.7	Analyzed personal injury and NAS claims.
Guo, Fang	10/2/2020	0.5	Discussed claims valuation analyses with team.
Guo, Fang	10/2/2020	1.1	Call with counsel regarding claims valuation analyses.
Guo, Ruihan	10/2/2020	0.6	Analyzed personal injury claims data.
Haque, Rezwan	10/2/2020	0.3	Reviewed protective order.
Haque, Rezwan	10/2/2020	0.3	Corresponded with counsel regarding claims valuation analyses.
Haque, Rezwan	10/2/2020	0.5	Discussed claims valuation analyses with team.
Haque, Rezwan	10/2/2020	1.1	Call with counsel regarding claims valuation.
Kovacheva, Penka	10/2/2020	1.1	Call with counsel to discuss claims estimation analyses.

Kovacheva, Penka	10/2/2020	1.6	Reviewed personal injury claims analyses and methodology.
Lee, James	10/2/2020	1.1	Call with counsel to discuss claims valuation analyses.
Lee, James	10/2/2020	1.5	Prepared materials for call with counsel.
Lee, James	10/2/2020	1.7	Analyzed personal injury claims data.
Woodhouse, Sally	10/2/2020	0.2	Reviewed summary of personal injury claims estimates.
Woodhouse, Sally	10/2/2020	0.5	Discussed claims valuation analyses with team.
Woodhouse, Sally	10/2/2020	1.1	Call with counsel regarding claims estimation analyses.
Yanguas, Maria Lucia	10/2/2020	0.5	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/2/2020	1.1	Reviewed and updated personal injury claims data analyses for call with counsel.
Yanguas, Maria Lucia	10/2/2020	1.3	Prepared work plan for personal injury claims valuation.
Abraham, Sarah M.	10/5/2020	0.3	Discussed claims valuation analyses with team.
Abraham, Sarah M.	10/5/2020	1.5	Designed analysis of personal injury claim valuation.
Aristidou, Andreas	10/5/2020	0.3	Discussed claims valuation analyses with team.
Aristidou, Andreas	10/5/2020	3.3	Reviewed public claimants' backup materials.
Bazak, Eric R.	10/5/2020	0.3	Discussed claims valuation analyses with team.
Chen, Yixin	10/5/2020	0.3	Discussed claims valuation analysis with team.
Chen, Yixin	10/5/2020	1.1	Updated analyses of personal injury claims data.
Chen, Yixin	10/5/2020	1.6	Conducted sensitivity analysis on personal injury claims data.
Desmedt, Maaike	10/5/2020	1.7	Analyzed personal injury and NAS claims.
Guo, Fang	10/5/2020	0.2	Reviewed academic literature regarding opioid-related treatment costs.
Guo, Fang	10/5/2020	0.3	Discussed claims valuation analyses with team.
Guo, Ruihan	10/5/2020	0.3	Discussed claims valuation analyses with team.
Haque, Rezwan	10/5/2020	0.3	Discussed claims valuation analyses with team.
King, Kyla M.	10/5/2020	0.3	Discussed claims valuation analyses with team.

Kovacheva, Penka	10/5/2020	0.2	Organized analysis of states' claims estimation.
Kovacheva, Penka	10/5/2020	0.3	Discussed claims valuation analyses with team.
Lee, James	10/5/2020	0.3	Discussed claims analyses with team.
Miller, Robert M.	10/5/2020	0.3	Discussed claims valuation analyses with team.
Russell, Nolan P.	10/5/2020	0.3	Discussed claims valuation analyses with team.
Russell, Nolan P.	10/5/2020	2.8	Analyzed personal injury claims data.
Woodhouse, Sally	10/5/2020	0.3	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/5/2020	0.3	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/5/2020	1.7	Reviewed personal injury claims valuation analyses.
Abraham, Sarah M.	10/6/2020	0.5	Edited analysis of personal injury claims valuation.
Chen, Yixin	10/6/2020	1.1	Conducted sensitivity analysis on personal injury claims data.
Chen, Yixin	10/6/2020	1.5	Updated analyses on personal injury claims data.
Desmedt, Maaike	10/6/2020	0.9	Updated estimates of personal injury and NAS claims.
Lee, James	10/6/2020	1.1	Reviewed analyses of personal injury claim forms data.
Yanguas, Maria Lucia	10/6/2020	2.3	Reviewed and updated personal injury claims valuation analyses.
Yanguas, Maria Lucia	10/6/2020	3.9	Analyzed personal injury claims data.
Abraham, Sarah M.	10/7/2020	2.1	Edited analysis of personal injury claims valuation.
Chen, Yixin	10/7/2020	0.7	Updated analyses on personal injury claims data.
Chen, Yixin	10/7/2020	2.9	Conducted sensitivity analysis on personal injury claims data.
Desmedt, Maaike	10/7/2020	0.8	Updated estimates of personal injury and NAS claims.
Guo, Fang	10/7/2020	3.6	Prepared work plan for robustness checks of public claims valuation.
Haque, Rezwan	10/7/2020	0.8	Reviewed public claims valuation analyses.
Haque, Rezwan	10/7/2020	1.8	Reviewed historical verdict and expert reports.
King, Kyla M.	10/7/2020	2.7	Compared historical verdict and public claimants' abatement plan.
King, Kyla M.	10/7/2020	3.9	Reviewed historical verdict and related expert's abatement plan.

Kovacheva, Penka	10/7/2020	0.3	Reviewed updated estimates of personal injury claims.
Kovacheva, Penka	10/7/2020	1.1	Reviewed and organized analysis of historical verdict regarding abatement program costs.
Lee, James	10/7/2020	2.9	Reviewed and summarized personal injury claims data analyses.
Russell, Nolan P.	10/7/2020	1.3	Updated personal injury claims data analysis.
Russell, Nolan P.	10/7/2020	4.0	Analyzed personal injury claims data.
Woodhouse, Sally	10/7/2020	0.2	Reviewed summary of personal injury settlements.
Woodhouse, Sally	10/7/2020	0.4	Reviewed analysis of historical verdict in relation to public claims estimation.
Yanguas, Maria Lucia	10/7/2020	1.7	Reviewed personal injury claims valuation analyses.
Yanguas, Maria Lucia	10/7/2020	3.8	Updated personal injury claims valuation analyses.
Abraham, Sarah M.	10/8/2020	0.4	Prepared materials for call with counsel regarding personal injury claims valuation.
Aristidou, Andreas	10/8/2020	3.0	Reviewed public claimants' backup materials.
Aristidou, Andreas	10/8/2020	3.8	Reviewed academic literature on future opioid use projections.
Bazak, Eric R.	10/8/2020	1.8	Checked exhibits of public claim sensitivity analyses.
Guo, Fang	10/8/2020	0.5	Reviewed public claimants' backup materials regarding future opioid use projections.
Guo, Fang	10/8/2020	0.5	Call with counsel regarding claims valuation analyses.
Guo, Fang	10/8/2020	1.3	Reviewed historical verdict regarding abatement costs.
Haque, Rezwan	10/8/2020	0.5	Call with counsel regarding claims valuation analyses.
Haque, Rezwan	10/8/2020	1.7	Reviewed historical verdict and expert reports.
Haque, Rezwan	10/8/2020	1.8	Reviewed public claims valuation analyses.
King, Kyla M.	10/8/2020	3.3	Reviewed historical verdict and related expert's abatement plan.
Kovacheva, Penka	10/8/2020	0.8	Reviewed analysis of historical verdict regarding abatement program costs.
Lee, James	10/8/2020	0.2	Prepared materials regarding personal injury claims data for call with counsel.
Miller, Robert M.	10/8/2020	1.3	Reviewed historical trial verdict.

Yanguas, Maria Lucia	10/8/2020	1.3	Reviewed personal injury claims valuation analyses.
Abraham, Sarah M.	10/9/2020	0.9	Call with counsel regarding personal injury claims valuation.
Aristidou, Andreas	10/9/2020	3.7	Reviewed public claimants' projections of future opioid use.
Chen, Yixin	10/9/2020	0.7	Updated analyses on personal injury claims data.
Guo, Fang	10/9/2020	0.8	Organized review of public claimants' backup materials.
Guo, Fang	10/9/2020	1.0	Call with counsel regarding claims valuation analyses.
Haque, Rezwan	10/9/2020	0.4	Discussed claims valuation analyses with team.
Haque, Rezwan	10/9/2020	0.7	Reviewed public claims valuation analyses.
Haque, Rezwan	10/9/2020	0.8	Reviewed historical verdict and expert reports to prepare for call with counsel.
Haque, Rezwan	10/9/2020	1.0	Call with counsel regarding claims valuation analyses.
King, Kyla M.	10/9/2020	0.9	Reviewed public claimants' methodology.
Kovacheva, Penka	10/9/2020	0.6	Call with counsel regarding claims valuation analyses.
Lee, James	10/9/2020	1.0	Call with counsel regarding claims valuation analyses.
Lee, James	10/9/2020	1.0	Prepared materials regarding claims valuation analyses for call with counsel.
Lee, James	10/9/2020	1.2	Updated analyses of personal injury claims data.
Woodhouse, Sally	10/9/2020	0.4	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/9/2020	0.4	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/9/2020	1.3	Analyzed personal injury claims data.
Yanguas, Maria Lucia	10/9/2020	1.5	Reviewed personal injury claims documents.
Yanguas, Maria Lucia	10/9/2020	3.0	Updated personal injury claims data valuation analyses.
Abraham, Sarah M.	10/12/2020	0.4	Discussed claims valuation analyses with team.
Aristidou, Andreas	10/12/2020	0.4	Discussed claims valuation analyses with team.
Aristidou, Andreas	10/12/2020	1.1	Reviewed historical trial transcripts.
Aristidou, Andreas	10/12/2020	2.0	Reviewed government expert report in historical settlement matter.
Aristidou, Andreas	10/12/2020	2.4	Reviewed academic literature on future opioid use projections.

Aristidou, Andreas	10/12/2020	2.6	Reviewed public claimants' backup materials.
Bazak, Eric R.	10/12/2020	0.4	Discussed claims valuation analyses with team.
Bazak, Eric R.	10/12/2020	1.0	Reviewed list of questions for public claimants.
Chen, Yixin	10/12/2020	0.4	Discussed claims valuation analyses with team.
Desmedt, Maaike	10/12/2020	0.4	Discussed claims valuation analyses with team.
Guo, Fang	10/12/2020	0.4	Discussed claims valuation analyses with team.
Guo, Fang	10/12/2020	0.6	Prepared materials for call with public claimants regarding public claims valuation analyses.
Guo, Fang	10/12/2020	0.8	Reviewed public claims valuation analyses.
Guo, Ruihan	10/12/2020	0.4	Discussed claims valuation analyses with team.
Haque, Rezwan	10/12/2020	0.4	Discussed claims valuation analyses with team.
Haque, Rezwan	10/12/2020	0.7	Reviewed public claims valuation analyses.
Haque, Rezwan	10/12/2020	1.2	Reviewed list of requests and questions for states regarding public claims.
King, Kyla M.	10/12/2020	0.4	Discussed claims valuation analyses with team.
King, Kyla M.	10/12/2020	2.2	Developed data requests for public claimants.
King, Kyla M.	10/12/2020	3.5	Developed methodology questions for public claimants.
Kovacheva, Penka	10/12/2020	0.4	Discussed claims valuation analyses with team.
Kovacheva, Penka	10/12/2020	0.8	Reviewed and updated data questions and production requests for public claimants.
Lee, James	10/12/2020	0.4	Discussed claims valuation analyses with team.
Miller, Robert M.	10/12/2020	0.4	Discussed claims valuation analyses with team.
Miller, Robert M.	10/12/2020	0.7	Reviewed list of data questions for public claimants.
Miller, Robert M.	10/12/2020	2.3	Updated list of data questions for public claimants.
Russell, Nolan P.	10/12/2020	0.4	Discussed claims valuation analyses with team.
Woodhouse, Sally	10/12/2020	0.4	Discussed claims valuation analyses with team.

Yanguas, Maria Lucia	10/12/2020	0.2	Analyzed personal injury claims data.
Yanguas, Maria Lucia	10/12/2020	0.4	Discussed claims valuation analyses with team.
Bazak, Eric R.	10/13/2020	3.2	Reviewed historical trial transcripts.
Guo, Fang	10/13/2020	1.4	Reviewed list of questions regarding public claims valuation analysis.
Guo, Fang	10/13/2020	2.6	Reviewed historical trial transcripts.
Haque, Rezwan	10/13/2020	0.6	Reviewed questions regarding states' claims methodology.
Haque, Rezwan	10/13/2020	0.8	Reviewed public claims valuation analyses.
King, Kyla M.	10/13/2020	1.2	Developed data requests for public claimants.
King, Kyla M.	10/13/2020	2.3	Developed methodology questions for public claimants.
King, Kyla M.	10/13/2020	3.5	Reviewed historical trial transcripts for public claims analysis.
Kovacheva, Penka	10/13/2020	0.2	Organized review of historical case materials regarding public claims estimates.
Miller, Robert M.	10/13/2020	0.3	Organized analyzes of public claim estimates.
Miller, Robert M.	10/13/2020	0.7	Updated abatement program cost exhibit.
Miller, Robert M.	10/13/2020	3.2	Reviewed historical trial transcripts.
Aristidou, Andreas	10/14/2020	1.5	Analyzed public claimants' projections of future opioid use.
Bazak, Eric R.	10/14/2020	4.2	Summarized historical trial transcripts.
Guo, Fang	10/14/2020	0.5	Call with counsel regarding public claims estimation.
Guo, Fang	10/14/2020	1.2	Reviewed list of questions regarding public claims valuation analyses.
Haque, Rezwan	10/14/2020	0.3	Corresponded with counsel regarding states' claims methodology.
Haque, Rezwan	10/14/2020	0.5	Call with counsel to discuss public claims estimation.
Haque, Rezwan	10/14/2020	1.5	Reviewed questions regarding states' claims methodology.
King, Kyla M.	10/14/2020	4.3	Reviewed historical trial transcripts for public claims analysis.
Kovacheva, Penka	10/14/2020	0.4	Reviewed and updated list of data questions for public claimants.
Kovacheva, Penka	10/14/2020	0.5	Call with counsel regarding public claims estimation.
Miller, Robert M.	10/14/2020	2.1	Reviewed historical trial transcripts.
Miller, Robert M.	10/14/2020	2.2	Analyzed public claims sensitivities.

Abraham, Sarah M.	10/15/2020	0.5	Prepared materials regarding personal injury claims valuation analyses for call with counsel.
Aristidou, Andreas	10/15/2020	0.8	Reviewed public claims backup materials.
Bazak, Eric R.	10/15/2020	3.9	Updated exhibits of public claims sensitivity analyses.
Guo, Fang	10/15/2020	0.6	Call with public claimants' consultants regarding public claims valuation analyses.
Guo, Fang	10/15/2020	1.9	Reviewed public claimants' sensitivity analyses.
Haque, Rezwan	10/15/2020	0.8	Prepared agenda for call with counsel regarding public claims estimates.
Haque, Rezwan	10/15/2020	0.8	Checked calculations for public claims valuation analyses.
Haque, Rezwan	10/15/2020	0.7	Call with counsel and public claimants' consultants regarding public claims analyses.
Haque, Rezwan	10/15/2020	2.2	Reviewed public claims valuation analyses.
King, Kyla M.	10/15/2020	1.5	Reviewed historical trial transcripts for public claims analysis.
King, Kyla M.	10/15/2020	1.6	Checked public claims sensitivity analysis.
Kovacheva, Penka	10/15/2020	0.5	Reviewed and updated agenda for call with counsel regarding public claims analyses.
Kovacheva, Penka	10/15/2020	0.6	Call with counsel and public claimants' consultants regarding public claims analyses.
Lee, James	10/15/2020	1.4	Prepared materials regarding claims valuation analyses for call with counsel.
Miller, Robert M.	10/15/2020	0.7	Prepared summary of historical trial transcripts.
Miller, Robert M.	10/15/2020	1.2	Updated public claims sensitivity analyses.
Woodhouse, Sally	10/15/2020	0.3	Reviewed comparison of historical verdict and public claims valuation estimates.
Abraham, Sarah M.	10/16/2020	0.9	Prepared work plan for personal injury valuation.
Abraham, Sarah M.	10/16/2020	1.0	Call with counsel regarding claims valuation analyses.
Aristidou, Andreas	10/16/2020	1.0	Analyzed public claimants' projections of future opioid use.
Bazak, Eric R.	10/16/2020	2.5	Checked exhibits of public claims sensitivity analyses.

Guo, Fang	10/16/2020	0.5	Discussed claims valuation analyses with team.
Guo, Fang	10/16/2020	0.9	Prepared materials for call with counsel regarding public claims valuation analyses.
Guo, Fang	10/16/2020	1.0	Call with counsel regarding claims valuation analyses.
Guo, Fang	10/16/2020	1.6	Prepared methodology for public claims sensitivity analyses.
Haque, Rezwan	10/16/2020	0.6	Reviewed public claims exhibits to prepare for call with counsel.
Haque, Rezwan	10/16/2020	0.8	Reviewed public claims valuation analyses.
Haque, Rezwan	10/16/2020	1.0	Call with counsel regarding claims valuation analyses.
King, Kyla M.	10/16/2020	3.3	Checked public claims sensitivity analysis.
Kovacheva, Penka	10/16/2020	0.3	Reviewed outline of claims valuation analyses received from counsel.
Kovacheva, Penka	10/16/2020	0.5	Discussed with team follow-up claims valuation analyses.
Kovacheva, Penka	10/16/2020	1.0	Call with counsel regarding claims valuation analyses.
Lee, James	10/16/2020	0.3	Prepared materials for call with counsel regarding claims valuation analyses.
Lee, James	10/16/2020	0.3	Updated personal injury claims data analyses.
Lee, James	10/16/2020	0.5	Discussed claims valuation analysis with team.
Lee, James	10/16/2020	1.0	Call with counsel regarding claims valuation analyses.
Miller, Robert M.	10/16/2020	0.4	Reviewed public claims sensitivity analyses.
Yanguas, Maria Lucia	10/16/2020	0.5	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/16/2020	0.9	Outlined next steps for personal injury claims data analyses.
Abraham, Sarah M.	10/19/2020	0.5	Discussed claims valuation analyses with team.
Aristidou, Andreas	10/19/2020	0.5	Discussed claims valuation analyses with team.
Aristidou, Andreas	10/19/2020	5.0	Checked public claims valuation analyses.
Bazak, Eric R.	10/19/2020	0.5	Discussed claims valuation analyses with team.
Bazak, Eric R.	10/19/2020	2.1	Updated exhibits of public claims sensitivity analyses.

17

Chen, Yixin	10/19/2020	0.5	Discussed claims valuation analyses with team.
Chen, Yixin	10/19/2020	1.2	Analyzed personal injury claims data.
Guo, Fang	10/19/2020	0.5	Discussed claims valuation analyses with team.
Guo, Fang	10/19/2020	0.7	Reviewed public claimants' backup materials.
Guo, Fang	10/19/2020	1.3	Reviewed public claims sensitivity analyses.
Guo, Ruihan	10/19/2020	0.5	Discussed claims valuation analyses with team.
Guo, Ruihan	10/19/2020	0.6	Reviewed personal injury claims data.
King, Kyla M.	10/19/2020	0.5	Discussed claims valuation analyses with team.
King, Kyla M.	10/19/2020	1.3	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	10/19/2020	2.2	Reviewed state claimants' data and document production.
Kovacheva, Penka	10/19/2020	0.3	Organized analysis of claims valuation estimates received from public claimants.
Lee, James	10/19/2020	0.5	Discussed claims valuation analysis with team.
Lee, James	10/19/2020	0.5	Reviewed personal injury claims analyses.
Miller, Robert M.	10/19/2020	0.5	Discussed claims valuation analyses with team.
Miller, Robert M.	10/19/2020	1.3	Checked sensitivity analyses of public claim estimates.
Russell, Nolan P.	10/19/2020	0.5	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/19/2020	0.5	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/19/2020	3.7	Updated personal injury claims data analyses.
Aristidou, Andreas	10/20/2020	1.7	Reviewed public claims backup materials.
Aristidou, Andreas	10/20/2020	2.0	Summarized public claimants' methodologies on future opioid use projections.
Aristidou, Andreas	10/20/2020	3.6	Checked future opioid use projections.
Bazak, Eric R.	10/20/2020	0.7	Checked sensitivity analysis of public claims estimates.
Chen, Yixin	10/20/2020	2.3	Checked adjustments to personal injury claims data analyses.
Chen, Yixin	10/20/2020	3.9	Analyzed personal injury claims data.

Guo, Fang	10/20/2020	1.0	Call with counsel and public claimants' consultants regarding public claims valuation analysis.
Guo, Fang	10/20/2020	1.1	Prepared work plan for public claims sensitivity analyses.
Guo, Fang	10/20/2020	2.4	Prepared work plan for public claim sensitivity analyses.
Guo, Fang	10/20/2020	3.4	Reviewed public claimants' backup materials regarding future opioid use projections.
Haque, Rezwan	10/20/2020	1.0	Call with counsel and public claimants' consultants to discuss valuation of public claims.
Haque, Rezwan	10/20/2020	1.3	Reviewed documentation of states' claims.
King, Kyla M.	10/20/2020	0.3	Reviewed state claimants' data and document production.
King, Kyla M.	10/20/2020	2.5	Checked sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	10/20/2020	1.0	Call with counsel and public claimants regarding methodology for public claim estimates.
Kovacheva, Penka	10/20/2020	1.1	Reviewed materials received from public claimants.
Miller, Robert M.	10/20/2020	2.5	Compiled backup materials for public claims analyses.
Miller, Robert M.	10/20/2020	2.9	Performed sensitivity analyses of public claim estimates.
Yanguas, Maria Lucia	10/20/2020	1.2	Reviewed public claims valuation materials produced by states.
Abraham, Sarah M.	10/21/2020	1.3	Reviewed personal injury claims data for claims valuation.
Aristidou, Andreas	10/21/2020	1.0	Checked public claimants' future opioid use projections.
Aristidou, Andreas	10/21/2020	1.7	Reviewed academic literature on future opioid use projections.
Aristidou, Andreas	10/21/2020	2.8	Summarized methodology for projecting future opioid use.
Aristidou, Andreas	10/21/2020	3.4	Reviewed public claimants' future opioid use projections.
Bazak, Eric R.	10/21/2020	3.4	Checked exhibits of public claims sensitivity analyses.
Chen, Yixin	10/21/2020	2.1	Updated analysis of personal injury claims data.
Chen, Yixin	10/21/2020	2.6	Analyzed personal injury claims data.
Guo, Fang	10/21/2020	0.8	Corresponded with public claimants' consultants regarding public claims backup materials.

Guo, Fang	10/21/2020	1.4	Prepared work plan for public claims sensitivity analyses.
Guo, Fang	10/21/2020	4.8	Drafted summary of third-party payer presentation.
Guo, Ruihan	10/21/2020	0.9	Checked sensitivity analyses of personal injury claims data.
Haque, Rezwan	10/21/2020	0.8	Reviewed third-party payer claims presentation.
Haque, Rezwan	10/21/2020	0.8	Reviewed public claims valuation analyses.
Haque, Rezwan	10/21/2020	1.6	Reviewed summary of third-party payer claims.
King, Kyla M.	10/21/2020	1.2	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	10/21/2020	1.8	Reviewed state claimants' data and document production.
Kovacheva, Penka	10/21/2020	1.4	Reviewed and updated summary analysis of third-party payer claimant presentation.
Lee, James	10/21/2020	2.5	Reviewed updated analyses of personal injury claims.
Miller, Robert M.	10/21/2020	1.5	Updated public claim sensitivity analysis exhibits.
Miller, Robert M.	10/21/2020	2.6	Calculated opioid prescription market shares.
Russell, Nolan P.	10/21/2020	0.5	Reviewed personal injury claims analyses.
Russell, Nolan P.	10/21/2020	3.3	Prepared code to analyze public claimants' model of future opioid use projections.
Yanguas, Maria Lucia	10/21/2020	2.3	Reviewed and updated personal injury claims valuation exhibits.
Abraham, Sarah M.	10/22/2020	1.0	Investigated robustness of personal injury claims valuation.
Aristidou, Andreas	10/22/2020	2.1	Reviewed public claimants' methodology for future opioid use projections.
Aristidou, Andreas	10/22/2020	2.5	Checked methodology for projecting future opioid use.
Aristidou, Andreas	10/22/2020	2.8	Updated summary of methodology for projecting future opioid use.
Bazak, Eric R.	10/22/2020	3.0	Checked sensitivity analysis of public claims estimates.
Chen, Yixin	10/22/2020	1.6	Analyzed public claim estimates.
Guo, Fang	10/22/2020	0.6	Edited summary of third-party payer presentation.
Guo, Fang	10/22/2020	2.9	Reviewed public claim sensitivity analyses.

Guo, Ruihan	10/22/2020	2.4	Updated personal injury claims valuation exhibits.
Guo, Ruihan	10/22/2020	3.9	Analyzed personal injury claims data.
Guo, Ruihan	10/22/2020	4.6	Checked sensitivity analyses of personal injury claims data.
Haque, Rezwan	10/22/2020	0.4	Reviewed agenda for call with counsel regarding claims valuation analyses.
Haque, Rezwan	10/22/2020	2.2	Reviewed public claims valuation analyses.
King, Kyla M.	10/22/2020	1.8	Checked sensitivity analyses of state claimants' estimates.
Lee, James	10/22/2020	5.3	Analyzed personal injury claims data.
Miller, Robert M.	10/22/2020	1.0	Checked calculation of opioid prescription market shares.
Miller, Robert M.	10/22/2020	1.2	Checked exhibit of public claims sensitivity analyses.
Miller, Robert M.	10/22/2020	2.5	Performed public claim sensitivity analyses.
Russell, Nolan P.	10/22/2020	4.0	Analyzed public claimants' model of future opioid use projections.
Yanguas, Maria Lucia	10/22/2020	0.5	Reviewed public claims backup materials regarding future opioid use.
Yanguas, Maria Lucia	10/22/2020	4.4	Checked personal injury claims valuation analyses.
Yanguas, Maria Lucia	10/22/2020	4.6	Reviewed public claims valuation materials produced by states.
Abraham, Sarah M.	10/23/2020	0.6	Discussed with team methodology for claims valuation analyses.
Abraham, Sarah M.	10/23/2020	1.0	Call with counsel regarding claims valuation.
Aristidou, Andreas	10/23/2020	0.5	Checked public claimant's methodology for future opioid use projections.
Aristidou, Andreas	10/23/2020	1.0	Updated summary of methodology for projecting future opioid use.
Aristidou, Andreas	10/23/2020	3.1	Checked summary of methodology for projecting future opioid use.
Aristidou, Andreas	10/23/2020	3.3	Reviewed academic literature on future opioid use projections.
Bazak, Eric R.	10/23/2020	1.5	Performed sensitivity analysis on opioid use disorder population.
Chen, Yixin	10/23/2020	3.9	Analyzed public claim estimates.
Guo, Fang	10/23/2020	1.0	Call with counsel regarding claims valuation.
Guo, Fang	10/23/2020	1.1	Prepared work plan for commercial claims valuation analyses.
Guo, Fang	10/23/2020	1.4	Reviewed public claimants' backup materials regarding future opioid use projections.

21

Guo, Fang	10/23/2020	1.6	Organized public claims sensitivity analyses.
Guo, Fang	10/23/2020	1.9	Reviewed public claimants' backup materials.
Guo, Ruihan	10/23/2020	1.6	Checked personal injury claims valuation exhibits.
Guo, Ruihan	10/23/2020	4.8	Updated personal injury claims valuation exhibits.
Haque, Rezwan	10/23/2020	0.6	Discussed claims valuation analyses with team.
Haque, Rezwan	10/23/2020	0.6	Call with expert regarding commercial claims valuation analyses.
Haque, Rezwan	10/23/2020	0.8	Reviewed public claims valuation exhibits to prepare for call with counsel.
Haque, Rezwan	10/23/2020	1.0	Call with counsel to discuss claims valuation analyses.
Haque, Rezwan	10/23/2020	1.6	Reviewed backup materials for public claims valuation produced by states.
Haque, Rezwan	10/23/2020	1.9	Reviewed academic literature on impact of opioid crisis on commercial claimants.
King, Kyla M.	10/23/2020	2.6	Performed sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	10/23/2020	0.6	Call with expert regarding commercial claims valuation analyses.
Kovacheva, Penka	10/23/2020	0.6	Discussed claims valuation analyses with team.
Kovacheva, Penka	10/23/2020	1.0	Reviewed summary of public and personal injury claims valuation analyses for call with counsel.
Kovacheva, Penka	10/23/2020	1.0	Call with counsel regarding claims valuation analyses.
Kovacheva, Penka	10/23/2020	2.3	Researched data availability for hospital and third-party payer claims valuation analyses.
Lee, James	10/23/2020	1.0	Call with counsel regarding claims valuation analyses.
Lee, James	10/23/2020	1.1	Analyzed personal injury claims data.
Lee, James	10/23/2020	2.2	Prepared materials for call with counsel regarding claims valuation analyses.
Miller, Robert M.	10/23/2020	0.8	Reviewed public claimants' backup materials.
Woodhouse, Sally	10/23/2020	0.6	Discussed claims valuation analyses with team.
Woodhouse, Sally	10/23/2020	0.6	Call with expert regarding claims valuation estimation.
Yanguas, Maria Lucia	10/23/2020	0.6	Discussed claims valuation analyses with team.

Yanguas, Maria Lucia	10/23/2020	1.6	Prepared materials for call with counsel regarding claims valuation analyses.
Yanguas, Maria Lucia	10/23/2020	2.4	Reviewed and summarized public claimants' methodology regarding future opioid use.
Yanguas, Maria Lucia	10/23/2020	4.6	Updated and checked personal injury claims valuation analyses.
Kovacheva, Penka	10/24/2020	0.5	Researched prior expert reports regarding hospital claims estimates.
Lee, James	10/24/2020	0.5	Reviewed actuarial report regarding potential claims for hospitals.
Lee, James	10/25/2020	0.5	Outlined methodology to value hospital claims.
Yanguas, Maria Lucia	10/25/2020	1.2	Updated summary of public claimants' methodology regarding future opioid use.
Aristidou, Andreas	10/26/2020	0.5	Discussed claims valuation analyses with team.
Aristidou, Andreas	10/26/2020	1.2	Reviewed sensitivity analysis of future opioid use projections.
Aristidou, Andreas	10/26/2020	3.1	Edited summary of future opioid use projections.
Aristidou, Andreas	10/26/2020	3.8	Performed sensitivity analysis on future opioid use projections.
Bazak, Eric R.	10/26/2020	0.5	Discussed claims valuation analyses with team.
Bazak, Eric R.	10/26/2020	3.8	Performed sensitivity analyses of public claims estimates.
Chen, Yixin	10/26/2020	0.5	Discussed claims valuation analyses with team.
Chen, Yixin	10/26/2020	1.9	Analyzed projections of future opioid use population.
Chen, Yixin	10/26/2020	3.1	Compiled supporting documents for personal injury claims data analysis.
Guo, Fang	10/26/2020	0.5	Discussed claims valuation analyses with team.
Guo, Fang	10/26/2020	1.6	Reviewed public claimants' backup materials.
Guo, Fang	10/26/2020	2.2	Reviewed public claims sensitivity analyses.
Guo, Ruihan	10/26/2020	0.5	Discussed claims valuation analyses with team.
Guo, Ruihan	10/26/2020	1.3	Checked personal injury claims data analyses.
Guo, Ruihan	10/26/2020	1.6	Reviewed and analyzed personal injury claims data.
Haque, Rezwan	10/26/2020	0.5	Discussed claims valuation analyses with team.

Haque, Rezwan	10/26/2020	1.2	Reviewed states' methodology for projecting opioid user population growth.
Haque, Rezwan	10/26/2020	1.5	Reviewed academic literature on impact of opioid crisis.
King, Kyla M.	10/26/2020	0.8	Reviewed state claimants' data and document production.
King, Kyla M.	10/26/2020	1.7	Checked sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	10/26/2020	0.3	Discussed claims valuation analyses with team.
Kovacheva, Penka	10/26/2020	0.5	Reviewed updates to analysis of personal injury claims.
Kovacheva, Penka	10/26/2020	1.4	Reviewed analysis of public claimants' methodology for future cost estimates.
Kovacheva, Penka	10/26/2020	1.5	Researched data sources for commercial claims analyses.
Lee, James	10/26/2020	0.4	Discussed claims valuation analyses with team.
Lee, James	10/26/2020	2.6	Analyzed personal injury claims data.
Miller, Robert M.	10/26/2020	0.5	Discussed claims valuation analyses with team.
Miller, Robert M.	10/26/2020	1.9	Updated exhibits of public claims sensitivity analyses.
Miller, Robert M.	10/26/2020	2.8	Reviewed public claimant's backup materials.
Russell, Nolan P.	10/26/2020	0.5	Discussed claims valuation analyses with team.
Russell, Nolan P.	10/26/2020	1.8	Checked sensitivity analysis of public claimants' model for future opioid use projections.
Yanguas, Maria Lucia	10/26/2020	0.5	Discussed claims valuation analyses with team.
Yanguas, Maria Lucia	10/26/2020	1.3	Updated personal injury claims valuation analyses.
Yanguas, Maria Lucia	10/26/2020	2.7	Updated summary of public claimants' methodology regarding future opioid use.
Yanguas, Maria Lucia	10/26/2020	3.7	Prepared work plan for robustness checks of future opioid use projections.
Abraham, Sarah M.	10/27/2020	3.7	Researched methodology for estimating third-party payer claims.
Aristidou, Andreas	10/27/2020	0.5	Reviewed public claimants' future opioid use projections.
Aristidou, Andreas	10/27/2020	2.5	Updated sensitivity analysis of future opioid use projections.
Aristidou, Andreas	10/27/2020	4.1	Checked sensitivity analysis of future opioid use projections.

Bazak, Eric R.	10/27/2020	2.1	Checked backup materials for public claims analyses.
Bazak, Eric R.	10/27/2020	2.8	Updated sensitivity analysis of opioid use disorder population.
Bazak, Eric R.	10/27/2020	3.2	Performed sensitivity analysis on public claims estimates.
Chen, Yixin	10/27/2020	1.4	Compiled supporting documents for personal injury claims data analysis.
Guo, Fang	10/27/2020	0.9	Call with counsel and public claimants' consultants regarding public claims valuation.
Guo, Fang	10/27/2020	1.1	Reviewed public claims sensitivity analyses.
Guo, Fang	10/27/2020	1.4	Reviewed public claimants' backup materials regarding future opioid use projections.
Guo, Fang	10/27/2020	3.4	Prepared work plan for commercial claims valuation.
Guo, Ruihan	10/27/2020	1.7	Checked personal injury claims data analyses.
Haque, Rezwan	10/27/2020	0.9	Call with public claimants' consultants and counsel to discuss analysis of public claims.
Haque, Rezwan	10/27/2020	1.8	Reviewed presentation on third-party payer claims.
Haque, Rezwan	10/27/2020	2.8	Reviewed analysis of hospital claims.
King, Kyla M.	10/27/2020	3.9	Reviewed state claimants' data and document production.
King, Kyla M.	10/27/2020	4.2	Checked sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	10/27/2020	0.9	Call with public claimants and counsel regarding public claimants' claim estimates.
Kovacheva, Penka	10/27/2020	1.0	Discussed claims valuation analyses with team member.
Kovacheva, Penka	10/27/2020	2.5	Analyzed methodology for commercial claimants' cost estimates.
Lee, James	10/27/2020	3.0	Prepared materials for call with counsel regarding third-party payer claims valuation.
Lee, James	10/27/2020	5.7	Reviewed industry and academic literature regarding third-party payer claims valuation.
Miller, Robert M.	10/27/2020	1.6	Checked sensitivity analyses on future opioid treatment costs.
Miller, Robert M.	10/27/2020	3.6	Performed sensitivity analyses on future opioid treatment costs.

Woodhouse, Sally	10/27/2020	1.0	Discussed claims valuation analyses with team member.
Yanguas, Maria Lucia	10/27/2020	1.7	Revised work plan for robustness checks of future opioid use projections.
Yanguas, Maria Lucia	10/27/2020	2.0	Prepared work plan for commercial claims analyses.
Yanguas, Maria Lucia	10/27/2020	2.5	Summarized hospital cost estimates and methodologies.
Yanguas, Maria Lucia	10/27/2020	4.9	Collected document relied upon for personal injury claims data analyses.
Abraham, Sarah M.	10/28/2020	1.0	Call with counsel regarding commercial claims valuation.
Abraham, Sarah M.	10/28/2020	1.8	Updated work plan to estimate third-party payer claims.
Aristidou, Andreas	10/28/2020	0.9	Updated work plan for additional analyses of future opioid use projections.
Aristidou, Andreas	10/28/2020	3.3	Checked sensitivity analysis of future opioid use projections.
Aristidou, Andreas	10/28/2020	3.8	Performed sensitivity analysis of future opioid use projections.
Bazak, Eric R.	10/28/2020	1.2	Researched data sources for public claims sensitivity analyses.
Bazak, Eric R.	10/28/2020	2.3	Performed sensitivity analysis on public claims estimates.
Bazak, Eric R.	10/28/2020	4.5	Reviewed public claimants' backup materials.
Chen, Yixin	10/28/2020	1.6	Compiled supporting documents for personal injury claims data analysis.
Chen, Yixin	10/28/2020	2.9	Checked updates to personal injury claims data analysis.
Guo, Fang	10/28/2020	1.0	Call with counsel regarding commercial claims valuation.
Guo, Fang	10/28/2020	1.7	Reviewed backup materials of public claim valuation produced by states.
Guo, Fang	10/28/2020	1.9	Reviewed public claims sensitivity analyses.
Guo, Fang	10/28/2020	2.7	Reviewed public claims sensitivity analyses.
Guo, Fang	10/28/2020	3.6	Reviewed public claims sensitivity analyses.
Guo, Ruihan	10/28/2020	1.2	Updated analyses of personal injury claims data.
Guo, Ruihan	10/28/2020	2.9	Checked personal injury claims data analyses.
Guo, Ruihan	10/28/2020	4.6	Analyzed personal injury claims data.
Haque, Rezwan	10/28/2020	1.0	Call with counsel to discuss commercial claims valuation.

Haque, Rezwan	10/28/2020	1.3	Reviewed analysis of public claims.
Haque, Rezwan	10/28/2020	2.3	Prepared agenda for call with counsel regarding commercial claims.
King, Kyla M.	10/28/2020	1.5	Performed robustness checks of state claimants' estimates.
King, Kyla M.	10/28/2020	3.4	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	10/28/2020	3.6	Reviewed state claimants' data and document production.
King, Kyla M.	10/28/2020	3.7	Updated exhibit of sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	10/28/2020	0.3	Reviewed updated public claims analyses.
Kovacheva, Penka	10/28/2020	1.0	Call with counsel regarding commercial claim estimation.
Kovacheva, Penka	10/28/2020	2.1	Reviewed and updated summary of commercial claim analyses.
Lee, James	10/28/2020	0.4	Reviewed updated personal injury claims data analyses.
Lee, James	10/28/2020	1.0	Call with counsel regarding commercial claims valuation analyses.
Lee, James	10/28/2020	1.5	Outlined methodology for third-party payer claims analyses.
Lee, James	10/28/2020	2.5	Reviewed third-party payer presentation and analyses.
Miller, Robert M.	10/28/2020	0.6	Created exhibits of public claims sensitivity analyses.
Miller, Robert M.	10/28/2020	3.3	Updated exhibits of public claims sensitivity analyses.
Miller, Robert M.	10/28/2020	3.9	Checked calculations of opioid prescription market shares.
Russell, Nolan P.	10/28/2020	2.3	Analyzed public claimants' model of future opioid use projections.
Russell, Nolan P.	10/28/2020	3.8	Analyzed and summarized results of public claimants' model for future opioid use projections.
Woodhouse, Sally	10/28/2020	0.4	Reviewed claims valuation analysis.
Yanguas, Maria Lucia	10/28/2020	1.2	Prepared hospital claims estimation work plan.
Yanguas, Maria Lucia	10/28/2020	2.8	Checked personal injury claims valuation analyses.
Yanguas, Maria Lucia	10/28/2020	4.2	Reviewed documents relied upon for personal injury claims data analyses.
Abraham, Sarah M.	10/29/2020	1.0	Call with counsel regarding commercial claims valuation.
Abraham, Sarah M.	10/29/2020	1.1	Revised work plan to estimate third-party payer claims.

Abraham, Sarah M.	10/29/2020	1.0	Call with expert regarding commercial claims valuation.
Aristidou, Andreas	10/29/2020	1.0	Checked sensitivity analysis of future opioid use projections.
Aristidou, Andreas	10/29/2020	3.2	Reviewed academic literature on future opioid use projections.
Aristidou, Andreas	10/29/2020	3.8	Performed sensitivity analysis of future opioid use projections.
Bazak, Eric R.	10/29/2020	0.3	Checked pharmaceutical market statistics.
Bazak, Eric R.	10/29/2020	3.0	Updated sensitivity analysis of public claims estimates.
Chen, Yixin	10/29/2020	1.8	Checked exhibits for future opioid use population projections.
Chen, Yixin	10/29/2020	3.8	Analyzed projections of future opioid use population.
Guo, Fang	10/29/2020	1.0	Call with expert regarding claims valuation analyses.
Guo, Fang	10/29/2020	1.0	Call with counsel to discuss commercial claims valuation.
Guo, Fang	10/29/2020	1.0	Call with counsel to discuss public claims valuation.
Guo, Fang	10/29/2020	2.3	Reviewed public claims sensitivity analyses.
Guo, Fang	10/29/2020	2.4	Prepared work plan for public claims sensitivity analyses.
Guo, Fang	10/29/2020	2.6	Edited exhibits on public claim sensitivity analysis.
Guo, Ruihan	10/29/2020	4.9	Reviewed and analyzed personal injury claims data.
Haque, Rezwan	10/29/2020	1.0	Call with expert to discuss commercial claims valuation.
Haque, Rezwan	10/29/2020	1.0	Call with counsel to discuss public claims valuation.
Haque, Rezwan	10/29/2020	1.0	Call with counsel to discuss commercial claims valuation.
Haque, Rezwan	10/29/2020	2.8	Reviewed analysis of hospital claims.
King, Kyla M.	10/29/2020	0.8	Prepared for analysis pharmaceutical market data.
King, Kyla M.	10/29/2020	1.9	Analyzed pharmaceutical market data.
King, Kyla M.	10/29/2020	3.8	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	10/29/2020	3.9	Cleaned and prepared for analysis pharmaceutical market data.
Kovacheva, Penka	10/29/2020	0.2	Call with counsel regarding commercial claims analyses.
Kovacheva, Penka	10/29/2020	0.9	Managed commercial claims analyses.

Kovacheva, Penka	10/29/2020	1.0	Call with expert regarding commercial claims analyses.
Kovacheva, Penka	10/29/2020	1.0	Call with counsel regarding public claims analyses.
Kovacheva, Penka	10/29/2020	1.2	Reviewed methodology and updates to public claims analyses.
Lee, James	10/29/2020	1.0	Call with counsel regarding commercial claims valuation analyses.
Lee, James	10/29/2020	3.3	Outlined next steps for analyses of third-party payer claims.
Lee, James	10/29/2020	7.0	Reviewed personal injury claims data and documents.
Miller, Robert M.	10/29/2020	3.2	Updated exhibits of public claims sensitivity analyses.
Russell, Nolan P.	10/29/2020	2.8	Analyzed public claimants' model of future opioid use projections.
Russell, Nolan P.	10/29/2020	3.8	Conducted sensitivity analysis of public claimants' model of future opioid use projections.
Woodhouse, Sally	10/29/2020	1.0	Call with expert to discuss claims valuation.
Woodhouse, Sally	10/29/2020	1.0	Call with counsel regarding commercial claims valuation estimation.
Yanguas, Maria Lucia	10/29/2020	2.2	Reviewed literature on hospital claims valuation and hospital profit margins.
Yanguas, Maria Lucia	10/29/2020	2.9	Reviewed robustness checks of future opioid use projections.
Yanguas, Maria Lucia	10/29/2020	5.0	Reviewed and updated methodology for personal injury claims valuation analyses.
Abraham, Sarah M.	10/30/2020	1.0	Call with counsel regarding claims valuation analyses.
Abraham, Sarah M.	10/30/2020	1.6	Managed data projects for third-party payer claims estimation.
Aristidou, Andreas	10/30/2020	0.5	Discussed claims valuation analyses with team.
Aristidou, Andreas	10/30/2020	2.3	Reviewed third-party payer claims valuation analyses.
Aristidou, Andreas	10/30/2020	3.2	Checked sensitivity analysis of future opioid use projections.
Bazak, Eric R.	10/30/2020	2.7	Reviewed government expert reports regarding NAS cost estimates.
Chen, Yixin	10/30/2020	1.2	Analyzed projections of future opioid use population.
Guo, Fang	10/30/2020	0.5	Discussed claims valuation analyses with team.
Guo, Fang	10/30/2020	1.0	Call with counsel regarding claims valuation analyses.

Guo, Fang	10/30/2020	2.4	Prepared work plan for NAS claims valuation analyses.
Guo, Fang	10/30/2020	2.6	Reviewed public claims sensitivity analyses.
Guo, Ruihan	10/30/2020	1.2	Analyzed third-party payer claims.
Guo, Ruihan	10/30/2020	3.8	Analyzed pharmaceutical market and drug expenditure data.
Haque, Rezwan	10/30/2020	0.5	Discussed claims valuation analyses with team.
Haque, Rezwan	10/30/2020	1.0	Call with counsel to discuss claims valuation analyses.
Haque, Rezwan	10/30/2020	1.8	Prepared work plan for hospital claims analysis.
Haque, Rezwan	10/30/2020	1.8	Reviewed analysis of hospital claims.
King, Kyla M.	10/30/2020	0.8	Reviewed prior government expert report in relation to NAS claims valuation.
King, Kyla M.	10/30/2020	2.2	Analyzed pharmaceutical market data.
King, Kyla M.	10/30/2020	3.4	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	10/30/2020	3.7	Updated sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	10/30/2020	0.2	Reviewed updates to public claims analyses.
Kovacheva, Penka	10/30/2020	0.5	Discussed claims valuation analyses with team.
Kovacheva, Penka	10/30/2020	0.9	Reviewed updates to personal injury claims analyses.
Kovacheva, Penka	10/30/2020	1.0	Discussed claims valuation analyses with counsel.
Lee, James	10/30/2020	1.0	Call with counsel regarding claims valuation analyses.
Lee, James	10/30/2020	2.0	Outlined analyses related to third-party payer claims.
Lee, James	10/30/2020	2.8	Prepared materials regarding personal injury claims data for call with counsel.
Miller, Robert M.	10/30/2020	1.5	Updated exhibits of public claims sensitivity analyses.
Miller, Robert M.	10/30/2020	3.3	Calculated opioid prescription market shares.
Woodhouse, Sally	10/30/2020	0.5	Discussed claims valuation analyses with team.
Woodhouse, Sally	10/30/2020	1.0	Call with counsel regarding claims valuation analyses.
Yanguas, Maria Lucia	10/30/2020	0.5	Reviewed hospital claims valuation work plan.
Yanguas, Maria Lucia	10/30/2020	0.5	Discussed claims valuation analyses with team.

Yanguas, Maria Lucia	10/30/2020	1.4	Reviewed documents relied upon for personal injury claims analyses.

Total	**853.0**
Grand Total	**868.3**